Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Other Non Operating Income (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Other Non Operating Income for 3 consecutive years, with -$46000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income fell 212.2% to -$46000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$282000.0, a 97.2% decrease, with the full-year FY2024 number at $75000.0, up 112.93% from a year prior.
  • Other Non Operating Income was -$46000.0 for Q3 2025 at Inhibrx Biosciences, up from -$246000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $60000.0 in Q4 2024 to a low of -$246000.0 in Q2 2025.
  • A 3-year average of -$62222.2 and a median of -$50000.0 in 2025 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 137.97% in 2024, then crashed 845.45% in 2025.
  • Inhibrx Biosciences' Other Non Operating Income stood at -$158000.0 in 2023, then surged by 137.97% to $60000.0 in 2024, then plummeted by 176.67% to -$46000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Other Non Operating Income are -$46000.0 (Q3 2025), -$246000.0 (Q2 2025), and -$50000.0 (Q1 2025).